Factor VII (FVII) deficiency is the most common autosomal recessive inherited bleeding disorder, with an estimated incidence of one per 500 000 cases in the general population. 1 Bleeding manifestations from FVII deficiency are heterogeneous in regard to severity and affected sites and, in many cases, correlate poorly with circulating FVII levels. Based on data from large registry studies, the International Society on Thrombosis and Haemostasis (ISTH) classifies FVII deficiency as: severe, FVII <10% (greatest risk for major spontaneous bleeding); moderate, 10%-20% (at risk for mild spontaneous or triggered bleeding); and mild, 20%-50% (usually
Pregnant patients with severe acute respiratory syndrome coronavirus 2, the virus responsible for the clinical condition newly described in 2019 as coronavirus disease 2019 (COVID-19) and illness severity to warrant intensive care have a complex disease process that must involve multiple disciplines. Guidelines from various clinical societies, along with direction from local health authorities, must be considered when approaching the care of an obstetric patient with known or suspected COVID-19. With a rapidly changing landscape, a simplified and cohesive perspective using guidance from different clinical society recommendations regarding the critically-ill obstetric patient with COVID-19 is needed. In this article, we synthesize various high-level guidelines of clinical relevance in the management of pregnant patients with severe disease or critical illness due to COVID-19.
Key Points
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.